New diabetes shot may beat standard insulin for blood sugar and weight
NCT ID NCT06871761
First seen Jan 17, 2026 · Last updated Apr 29, 2026 · Updated 14 times
Summary
This study tested a new injectable medicine, HR17031, against a standard insulin (insulin glargine) in 393 adults with type 2 diabetes. Participants had not achieved good blood sugar control despite using basal insulin and metformin. The main goal was to see which treatment better lowered HbA1c (a blood sugar marker) over 26 weeks, while also tracking weight changes and side effects like low blood sugar.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADULT PATIENTS WITH TYPE 2 DIABETES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai Zhu Xianyi Memorial Hospital, Tianjin Medical University
Tianjin, Tianjin Municipality, 300400, China
Conditions
Explore the condition pages connected to this study.